title: Outcome based staging for clinically localized adenocarcinoma of the prostate.
abstract: OBJECTIVE
  Some patients with clinically localized prostate cancer are not cured after radical prostatectomy because of the presence of occult systemic disease. The American Joint Commission on Cancer staging classification for prostate cancer does not reliably distinguish between clinically localized patients who are likely or unlikely to be cured after local therapy. This project was undertaken to develop a staging system capable of predicting long-term outcome after radical prostatectomy on the basis of the clinical parameters obtained routinely during the standard workup for patients with adenocarcinoma of the prostate.
  
  
  METHODS
  A total of 688 clinically localized prostate cancer patients managed with a radical retropubic prostatectomy for adenocarcinoma of the prostate between 1989 and 1996 was evaluated for clinical features predictive of time to prostate specific antigen (PSA) failure using a Cox regression multivariate analysis. A recently defined clinical factor called the calculated prostate cancer volume and its ability to predict time to PSA failure in conjunction with PSA, biopsy Gleason score and clinical stage were evaluated.
  
  
  RESULTS
  The calculated prostate cancer volume (p <0.0001) and the pretreatment PSA (p <0.001) provided the optimal staging system for predicting freedom from PSA failure after radical prostatectomy.
  
  
  CONCLUSIONS
  The calculated prostate cancer volume and PSA may provide clinically useful information regarding outcome after radical prostatectomy, enabling the selection of a therapeutic approach for an individual patient with clinically localized disease. Validation of this staging system is needed.
authors.affiliation: Joint Center for Radiation Therapy, Harvard Medical School, Boston, Massachusetts, USA.
authors.forename: A V
authors.initials: AV
authors.lastname: D'Amico
authors.forename: R
authors.initials: R
authors.lastname: Whittington
authors.forename: D
authors.initials: D
authors.lastname: Schultz
authors.forename: S B
authors.initials: SB
authors.lastname: Malkowicz
authors.forename: J E
authors.initials: JE
authors.lastname: Tomaszewski
authors.forename: A
authors.initials: A
authors.lastname: Wein
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000401:mortality / Q000473:pathology*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology*; D015996:Survival Rate
chemical_list: D017430:Prostate-Specific Antigen